Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice

Molecular Pharmacology

Volumn 71, Issue 3, 2007, Pages 826-834

  Siu, Eric C K ^a   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Department of Pharmacology ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A5; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC DIFFERENCE; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; COTININE; CYTOCHROME P-450 CYP2D6; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MIXED FUNCTION OXYGENASES; NICOTINE; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; SPECIES SPECIFICITY;

EID: 33847109839     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.032086     Document Type: Article

References (40)

1. Ariyoshi N, Sawamura Y, and Kamataki T (2001) A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 281:810-814.
2. Aschhoff S, Schroff K-C, Wildenauer DB, and Richter E (1999) Nicotine consumption of several mouse strains using a two bottle choice paradigm. J Exp Anim Sci 40:171-177.
3. Benowitz NL (1999) Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect 107 (Suppl 2):349-355.
4. Benowitz NL, Kuyt F, Jacob P 3rd, Jones RT, and Osman AL (1983) Cotinine disposition and effects. Clin Pharmacol Ther 34:604-611.
5. Benowitz NL, Lessov-Schlaggar CN, Swan GE, and Jacob P 3rd (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480-488.
6. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, and Jacob P 3rd (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291:1196-1203.
7. Buccafusco JJ and Terry AV Jr (2003) The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 72:2931-2942.
8. Crooks PA and Dwoskin LP (1997) Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54:743-753.
9. Damaj MI, Siu EC, Seller EM, Tyndale RF, and Martin BR (2007) Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257.
10. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, Dwoskin LP, and Crooks PA (2002) Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke. J Clin Psychopharmacol 22:496-501.
11. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, and Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:64-72.
12. 3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther 288:905-911.
13. Ghosheh O and Hawes EM (2002) Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. Drug Metab Dispos 30:1478-1483.
14. Hatsukami D, Lexau B, Nelson D, Pentel PR, Sofuoglu M, and Goldman A (1998a) Effects of cotinine on cigarette self-administration. Psychopharmacology (Berl) 138:184-189.
15. Hatsukami D, Pentel PR, Jensen J, Nelson D, Allen SS, Goldman A, and Rafael D (1998b) Cotinine: effects with and without nicotine. Psychopharmacology (Berl) 135:141-150.
16. He XY, Shen J, Hu WY, Ding X, Lu AY, and Hong JY (2004) Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys 427:143-153.
17. Henningfield JE and Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743-750.
18. Hukkanen J, Jacob P 3rd, and Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79-115.
19. Keenan RM, Hatsukami DK, Pentel PR, Thompson TN, and Grillo MA (1994) Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin Pharmacol Ther 55:581-590.
20. Lindberg RL, Juvonen R, and Negishi M (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh. Pharmacogenetics 2:32-37.
21. Lockman PR, McAfee G, Geldenhuys WJ, Van der Schyf CJ, Abbruscato TJ, and Allen DD (2005) Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J Pharmacol Exp Ther 314:636-642.
22. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, and Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409.
23. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
24. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K, Nohmi T, Funae Y, Imaida K, and Kamataki T (2005) Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced mouse lung adenomas. Carcinogenesis 26:1947-1955.
25. Murphy SE, Johnson LM, and Pullo DA (1999) Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem Res Toxicol 12:639-645.
26. Murphy SE, Raulinaitis V, and Brown KM (2005) Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166-1173.
27. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996a) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015.
28. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996b) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
29. Nakayama H, Okuda H, Nakashima T, Imaoka S, and Funae Y (1993) Nicotine metabolism by rat hepatic cytochrome P450s. Biochem Pharmacol 45:2554-2556.
30. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, and Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626.
31. Schoedel KA, Sellers EM, Palmour R, and Tyndale RF (2003) Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63:96-104.
32. Siu EC, Wildenauer DB, and Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184:401-408.
33. Sparks JA and Pauly JR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57BL/6 mice. Psychopharmacology (Berl) 141:145-153.
34. Stolerman IP, Naylor C, Elmer GI, and Goldberg SR (1999) Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology (Berl) 141:297-306.
35. Urakawa N, Nagata T, Kudo K, Kimura K, and Imamura T (1994) Simultaneous determination of nicotine and cotinine in various human tissues using capillary gas chromatography/mass spectrometry. Int J Legal Med 106:232-236.
36. Vainio PJ and Tuominen RK (2001) Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. Nicotine Tob Res 3:177-182.
37. van Iersel M, Walters DG, Price RJ, Lovell DP, and Lake BG (1994) Sex and strain differences in mouse hepatic microsomal coumarin 7-hydroxylase activity. Food Chem Toxicol 32:387-390.
38. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, and Yokoi T (2004) Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 22:419-425.
39. Yamazaki H, Inoue K, Hashimoto M, and Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73:65-70.
40. Zarrindast MR, Faraji N, Rostami P, Sahraei H, and Ghoshouni H (2003) Crosstolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav 74:363-369.